Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02104050
Recruitment Status : Completed
First Posted : April 4, 2014
Last Update Posted : October 6, 2017
Sponsor:
Information provided by (Responsible Party):
Olatec Therapeutics LLC

Tracking Information
First Submitted Date  ICMJE March 28, 2014
First Posted Date  ICMJE April 4, 2014
Last Update Posted Date October 6, 2017
Study Start Date  ICMJE April 2014
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 3, 2014)
Pain on Movement [ Time Frame: Baseline to Week 6 ]
Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02104050 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 3, 2014)
  • Current Knee Pain [ Time Frame: Baseline (pre-dose) to Baseline (50-min post-dose) ]
    After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
  • WOMAC Pain Subscale [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
  • WOMAC Physical Function Subscale [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
  • Global Rating of Disease [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    Subjects will complete the assessment on a 100-mm Visual Analog Scale (with anchors 0=very good; 100=very poor) in response to the question, 'Considering all the ways osteoarthritis affects you, how well are you doing?'
  • Current Knee Pain [ Time Frame: Baseline to Hours 2-6 ]
    After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
  • WOMAC Stiffness Subscale [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
  • Pain on Movement (VAS, in-clinic) [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
  • Pain on Movement (11-point NRS, diary) [ Time Frame: Baseline through Week 6 ]
    All evaluations will be on the 11-point Numerical Rating Scale (with anchors 0=no pain; 100=extreme pain) and in response to the following instructions: Please put an "X" over the one number below that best describes your average study knee pain while moving during your daily activities since you woke up this morning.
  • Use of Rescue Medication [ Time Frame: Baseline through Week 6 ]
    Subjects will record the amount, time/date and dose of Rescue Medication use throughout the trial.
  • Short Form 12v2 Health Survey [ Time Frame: Baseline to Weeks 2, 4 and 6 ]
    The SF-12v2 Health Survey is a multipurpose short-form (SF) general health survey comprised of 12 questions to measure functional health and well-being from the subject's perspective.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: August 7, 2015)
  • Physical Examination: Number of subjects with clinically significant changes in Physical Examination in major body systems (HEENT, Neck, Cardiovascular, Abdominal, Respiratory, Musculoskeletal, Extremities Skin or Other) [ Time Frame: Baseline through Week 8 ]
  • Vital Signs: Change from Baseline in Heart Rate (beats per minute) [ Time Frame: Baseline through Week 8 ]
  • Vital Signs: Change from Baseline in Supine Diastolic Blood Pressure [mmHg] [ Time Frame: Baseline through Week 8 ]
  • Vital Signs: Change from Baseline in Supine Systolic Blood Pressure [mmHg] [ Time Frame: Baseline through Week 8 ]
  • Vital Signs: Change from Baseline in Body Temperature (axillary) [°C] [ Time Frame: Baseline through Week 8 ]
  • Vital Signs: Change from Baseline in respiration rate (respirations per minute) [ Time Frame: Baseline through Week 8 ]
  • Number of Adverse Events [ Time Frame: Screening through Week 8 ]
  • Number of Serious Adverse Events [ Time Frame: Screening through Week 8 ]
  • Number of Treatment Emergent Adverse Events [ Time Frame: Baseline through Week 8 ]
  • Percent of Subjects experiencing Adverse Events [ Time Frame: Screening through Week 8 ]
  • Percent of Subjects experiencing Serious Adverse Events [ Time Frame: Screening through Week 8 ]
  • Percent of Subjects experiencing Treatment Emergent Adverse Events [ Time Frame: Baseline through Week 8 ]
  • Safety Labs: Hematology [ Time Frame: Baseline through Week 8 ]
    Blood will be drawn for hematology laboratory analysis
  • Safety Labs: Chemistry [ Time Frame: Baseline through Week 8 ]
    Blood will be drawn for chemistry laboratory analysis
Original Other Pre-specified Outcome Measures
 (submitted: April 3, 2014)
  • Physical Examination [ Time Frame: Baseline through Week 8 ]
    A standard physical examination covering the major body systems will be completed at the Screening, Baseline (prior to randomization) and Week 6 visits.
  • Vital Signs [ Time Frame: Baseline through Week 8 ]
    Pulse, resting blood pressure, temperature and respiration will be collected.
  • Safety Laboratory Measures [ Time Frame: Baseline through Week 8 ]
    Blood will be drawn for hematology and chemistry laboratory analysis will be performed.
  • Adverse Events [ Time Frame: Screening through Week 8 ]
    Adverse events will be collected starting immediately after the ICF is signed and continuing through Week 8.
 
Descriptive Information
Brief Title  ICMJE Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
Official Title  ICMJE A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy
Brief Summary The objectives of this trial are to investigate the efficacy and safety of six weeks of treatment with OLT1177 Gel in subjects with moderate to severe pain associated with osteoarthritis of the knee following cessation of pain therapy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Osteoarthritis
  • Pain
Intervention  ICMJE
  • Drug: Placebo Gel
    6 mL of Placebo Gel administered TID for 6 weeks
  • Drug: OLT1177 Gel
    6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Study Arms  ICMJE
  • Placebo Comparator: Placebo Gel
    6 mL of Placebo Gel administered TID for 6 weeks
    Intervention: Drug: Placebo Gel
  • Experimental: OLT1177 Gel
    6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
    Intervention: Drug: OLT1177 Gel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 27, 2015)
202
Original Estimated Enrollment  ICMJE
 (submitted: April 3, 2014)
200
Actual Study Completion Date  ICMJE August 2015
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age 45 to 80 years old, inclusive
  • Clinical diagnosis of osteoarthritis in one target knee based on the following American College of Rheumatology (ACR) criteria:

    1. Knee Pain
    2. At least 1 of 3:

      • Age > 50 years
      • Morning stiffness lasting < 30 minutes
      • Crepitus on motion
    3. Osteophytes on radiograph
  • Symptoms associated with osteoarthritis of the knee (including pain) for ≥ 6 months prior to Screening
  • Knee pain associated with osteoarthritis, which required NSAID or other therapy for ≥ 15 days during the preceding month
  • Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 2 or 3 in the target knee (does not include borderline Grade 2), as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit. (Sharpening of the tibial spine is not considered to be an osteophyte) (See Appendix 4 for additional details)
  • Meets pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
  • No clinically significant change in physical activity and/or therapy for the past 3 months
  • Able to provide written informed consent prior to initiation of any clinical trial-related procedures; and willing and able, in the opinion of the Investigator, to comply with all requirements of the clinical trial for the duration of the trial (such requirements include, but are not limited to: attending all study visits, refraining from elective surgery or extensive travel during participation)

Exclusion Criteria:

General

  • Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential may not be entered into the study if:

    1. They are or intend to become pregnant (including use of fertility drugs) during the study
    2. They are nursing
    3. They are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the 9-week clinical trial.)
  • Body Mass Index (BMI) over 40
  • A history of osteoarthritis symptoms that are completely non-responsive to non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator
  • Planned change (increase or decrease) in subject's level of physical activity (e.g., aerobic or anaerobic exercise) during the 6-week Treatment Period following randomization
  • Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
  • Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01 or OLT1177-02

Pain Related

  • Does not meet pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
  • Clinically significant joint (other than the knee) or general pain at Baseline, at the discretion of the Investigator

Musculoskeletal Related

  • Clinically significant, excessive effusion heat and/or redness in the target knee as determined by the Investigator
  • Knock-kneed or bow-legged, as defined by a valgus or varus deformity of ≥ 15 degrees
  • Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 0, 1 or 4 in the target knee, as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit (sharpening of the tibial spine is not considered to be an osteophyte)
  • Documented history of clinically significant pain associated with osteoarthritis of the spine or hips, at the discretion of the Investigator
  • Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia
  • Clinically significant medio-lateral and/or anterior-posterior instability, at the discretion of the Investigator
  • Open surgery of the target knee within the prior year or surgery to the contralateral knee or other weight-bearing joint within the prior year, if at the discretion of the Investigator it would interfere with the study. If subject had open surgery more than one-year prior, Sponsor's designated rheumatologist must confirm that such surgery did not have any negative impact or consequence to the target knee (e.g., deformity of angle to the bone, bone on bone, locking joints, etc.)
  • Arthroscopic surgery of the target knee within the prior six months
  • Any acute or chronic injury, other than osteoarthritis in the target knee, that will be treated during the trial with any medication not allowed during the Treatment Period
  • Prior surgery of the target knee requiring insertion of a medical device or surgical hardware (e.g., screws)
  • Any major trauma or injury (including sports injuries) to the target knee in the past 12 months
  • Documented history of inflammatory joint disease, including but not limited to: rheumatoid arthritis, gout, pseudogout, Paget's disease, psoriatic arthritis, ankylosing spondylitis, chronic inflammatory disease (e.g., colitis), fibromyalgia (diagnosed in accordance with ACR criteria, as applicable), articular fracture, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g., hypermobility) or collagen gene mutations
  • Any planned interventional and/or surgical procedure during the 6-week Treatment Period following randomization

Concomitant Conditions, Diseases, Medications/Therapies and Medical History Related

  • Any use of Rescue Medication within 24 hours prior to the Baseline visit or use of any other pain medication within 7 days prior to Baseline visit
  • Uncontrolled hypertension, defined as blood pressure ≥ 150/95 mmHg
  • A history of uncontrolled and untreated diabetes mellitus with an HbA1c level > 8; or blood sugar levels that are outside of the normal range and HbA1c level > 8 is subsequently confirmed
  • Any inflammatory skin condition over the target knee application area
  • Use of any prohibited concomitant medications/therapies during the 7-day Washout Period or planned use of any prohibited concomitant medications/therapies during the 6 week Treatment Period
  • Use of intraarticular or intramuscular steroids in the target knee within the previous 3 months or in any other joint within the previous 30 days
  • Use of intraarticular hyaluronate in the target knee within the previous 6 months or in any other joint within the previous 30 days
  • Current substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse (including alcoholism and/or addiction to pain medications) that is determined at the discretion of the Investigator as likely to interfere with trial assessments or recur during the trial
  • Use of any systemic (oral or parenteral) corticosteroids within the prior month
  • Uncontrolled psychiatric conditions (e.g., mania, depression, anxiety, substance dependence of any kind) that would impair the subject from safely participating in the trial, including completing any protocol requirements
  • Evidence of cognitive impairment including dementia that may interfere with subject's ability to complete daily pain diaries requiring recall of average pain level in the past 24 hours
  • Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological or neurological disease or prior surgery that may interfere with the subject successfully completing the trial, including completing any protocol requirements as determined by the Investigator
  • History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
  • Diagnosed with any form of cancer within the past 5 years, except for treated basal cell or squamous cell carcinoma of the skin
  • Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
  • Active infection within 3 days of the Baseline visit
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 45 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02104050
Other Study ID Numbers  ICMJE OLT1177-03
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Olatec Therapeutics LLC
Study Sponsor  ICMJE Olatec Therapeutics LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: William Cunningham, MD, FAAD Cu-Tech, LLC
PRS Account Olatec Therapeutics LLC
Verification Date April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP